Salt-inducible Kinase (SIK) Inhibitor

Salt-inducible Kinase (SIK) Inhibitors (26):

Cat. No.	Product Name	Effect	Purity

HY-15776

HG-9-91-01	Inhibitor	99.77%
HG-9-91-01 is a potent and highly selective salt-inducible kinase (SIK) inhibitor with IC₅₀s of 0.92 nM, 6.6 nM and 9.6 nM for SIK1, SIK2 and SIK3 respectively.

HY-101147

YKL-05-099	Inhibitor	99.76%
YKL-05-099 is a salt-inducible kinase (SIK) inhibitor. YKL-05-099 binds to SIK1 and SIK3 with IC₅₀s of ~10 and ~30 nM, respectively. YKL-05-099 has slightly less potent SIK2-inhibitory (IC₅₀=40 nM).

HY-120877

MRT199665	Inhibitor	99.74%
MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC₅₀s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively. MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370.

HY-120856

ARN-3236	Inhibitor	99.66%
ARN-3236 is an oral active and selective inhibitor of salt-inducible kinase 2 (SIK2), with IC₅₀s of <1 nM, 21.63 nM and 6.63 nM for SIK2, SIK1 and SIK3, respectively. Has anti-cancer activity.

HY-129141

YKL-06-062	Inhibitor	99.44%
YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor with an IC₅₀ of 2.12 nM/1.40 nM/2.86 nM for SIK1, SIK2 and SIK3, respectively.

HY-171590

SIK2-IN-3	Inhibitor
SIK2-IN-3 is an orally active SIK1/2 selective inhibitor (IC₅₀: 0.128/0.084 μM). SIK2-IN-3 inhibits CRTC3 phosphorylation and myeloid cell pro-inflammatory cytokine production. SIK2-IN-3 ameliorates systemic and tissue inflammatory responses in a mouse anti-CD40 colitis model.

HY-170237

SIK2/3-IN-1	Inhibitor
SIK2/3-IN-1 (Compound 7S) is a selectively inhibitory agent of SIK2/3 with oral activity. SIK2/3-IN-1 can significantly inhibit tumor growth (without any body weight loss) in the MV4-11 AML mice CDX model. SIK2/3-IN-1 can be used in the research of MEF2C-dependent acute myeloid leukemia.

HY-150203

GLPG3970	Inhibitor	99.64%
GLPG3970 (compound 88) is a first-in-class SIK2/SIK3 inhibitor. GLPG3970 can be used for the research of inflammation and autoimmune disease.

HY-157442

GLPG3312	Inhibitor	98.57%
GLPG3312 (Compound 28) is an orally active SIK inhibitor with IC₅₀ values of 2.0 nM, 0.7 nM and 0.6 nM for SIK1, SIK2 and SIK3, respectively. GLPG3312 exhibits anti-inflammatory and immunomodulatory activity in vitro on human primary myeloid cells and in vivo in mouse models. GLPG3312 has good oral bioavailability and can be used for research on inflammatory and immune diseases.

HY-120056

YKL-06-061	Inhibitor	99.66%
YKL-06-061 is a potent, selective, second-generation salt-inducible kinase (SIK) inhibitor with IC₅₀ values of 6.56 nM/1.77 nM/20.5 nM for SIK1/2/3, respectively.

HY-N1570

Pterosin B	Inhibitor	99.92%
Pterosin B is an orally active indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes.

HY-138001

WH-4-025	Inhibitor	99.31%
WH-4-025 is a Salt-inducible kinase (SIK) inhibitor (WO2016023014 A2).

HY-139253

MRIA9	Inhibitor	98.80%
MRIA9 is an ATP-competitive, pan Salt-Inducible kinase (SIK) and PAK2/3 inhibitor, with IC₅₀ values of 516 nM, 180 nM and 127 nM for SIK1, SIK2 and SIK3, respectively.

HY-RS12917

SIK3 Human Pre-designed siRNA Set A	Inhibitor
SIK3 Human Pre-designed siRNA Set A contains three designed siRNAs for SIK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-120877A

(R)-MRT199665	Inhibitor	98.70%
(R)-MRT199665 is an isomer of MRT199665 (HY-120877). MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC₅₀s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively. MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370.

HY-159657

SIK-IN-4	Inhibitor	98.83%
SIK-IN-4 (compound 34) is a SIK inhibitor, with IC₅₀ values of 1.2 nM, 0.9 nM and 1.8 nM for SIK1, SIK2 and SIK3, respectively.

HY-RS12918

Sik3 Mouse Pre-designed siRNA Set A	Inhibitor
Sik3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sik3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS12915

Sik2 Mouse Pre-designed siRNA Set A	Inhibitor
Sik2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sik2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-149365

SIKs-IN-1	Inhibitor
SIKs-IN-1 (compound 8h), a pyrimidine-5-carboxamide derivative, is a Salt-inducible kinases (SIKs) inhibitor. SIKs regulates the transformation of M1/M2 macrophages, involving in inflammation process. SIKs-IN-1 inhibits SIK activity, up-regulates anti-inflammatory cytokine IL-10, but down-regulates pro-inflammatory cytokine IL-12. SIKs-IN-1 shows excellent anti-inflammatory effects in a DSS-induced colitis model.

HY-RS12912

Sik1 Mouse Pre-designed siRNA Set A	Inhibitor
Sik1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sik1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Name
Email *

	Sorry, but the email address you supplied was invalid.